Skip to main content
Top
Published in: Discover Oncology 1/2023

Open Access 01-12-2023 | Kidney Cancer | Research

Exploring oncogenes for renal clear cell carcinoma based on G protein-coupled receptor-associated genes

Authors: Chengcun Zhu, Zhou Sun, Jie Wang, Xiangdi Meng, Zhaosen Ma, Rui Guo, Jiqiang Niu, Lisa Jia Tran, Jing Zhang, Tianxiao Jiang, Yunfei Liu, Fangdie Ye, Baoluo Ma

Published in: Discover Oncology | Issue 1/2023

Login to get access

Abstract

G protein-coupled receptors (GPCRs) are a class of receptors on cell membranes that regulate various biological processes in cells, such as cell proliferation, differentiation, migration, apoptosis, and metabolism, by interacting with G proteins. However, the role of G protein-coupled receptors in predicting the prognosis of renal clear cell carcinoma is still unknown. The transcriptome data and clinical profiles of renal clear cell carcinoma patients, were downloaded from TCGA databases, and the validation group data were downloaded from number GSE167573, including 63 tumor samples and 14 normal samples. Single-cell RNA sequencing data were downloaded from the GEO database, No. GSE152938 and selected samples were used for GSEA enrichment analysis, WGCNA subgroup analysis, single-cell data analysis, and mutation analysis to explore the role of G protein-coupled receptor-related genes in the diagnosis and prognosis of renal clear cell carcinoma and to verify their reliability with cellular experiments. Finally, this study establishes a disease model based on G protein-coupled receptor-related genes, which may help to propose targeted therapeutic regimens in different strata of renal cell carcinoma patients.Author names: Please confirm if the author names are presented accurately and in the correct sequence (given name, middle name/initial, family name). Author: Given name [Lisa Jia] Last name [Tran].It's ok!
Literature
1.
go back to reference Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–87.CrossRefPubMed Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–87.CrossRefPubMed
2.
3.
go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
4.
go back to reference Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.CrossRefPubMed Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.CrossRefPubMed
6.
7.
go back to reference Linehan WM, Ricketts CJ. Kidney cancer in 2016: RCC—advances in targeted therapeutics and genomics. Nat Rev Urol. 2017;14(2):76–8.CrossRefPubMed Linehan WM, Ricketts CJ. Kidney cancer in 2016: RCC—advances in targeted therapeutics and genomics. Nat Rev Urol. 2017;14(2):76–8.CrossRefPubMed
8.
go back to reference Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary SysTME and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93–105.CrossRefPubMed Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary SysTME and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93–105.CrossRefPubMed
9.
go back to reference Hsieh JJ, Le VH, Oyama T, Ricketts CJ, Ho TH, Cheng EH. Chromosome 3p loss-orchestrated VHL, HIF, and epigenetic deregulation in clear cell renal cell carcinoma. J Clin Oncol. 2018;36(36):Jco2018792549.CrossRefPubMed Hsieh JJ, Le VH, Oyama T, Ricketts CJ, Ho TH, Cheng EH. Chromosome 3p loss-orchestrated VHL, HIF, and epigenetic deregulation in clear cell renal cell carcinoma. J Clin Oncol. 2018;36(36):Jco2018792549.CrossRefPubMed
10.
go back to reference Acker T, Diez-Juan A, Aragones J, Tjwa M, Brusselmans K, Moons L, et al. Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell. 2005;8(2):131–41.CrossRefPubMed Acker T, Diez-Juan A, Aragones J, Tjwa M, Brusselmans K, Moons L, et al. Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell. 2005;8(2):131–41.CrossRefPubMed
11.
go back to reference Capitanio U, Cloutier V, Zini L, Isbarn H, Jeldres C, Shariat SF, et al. A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study. BJU Int. 2009;103(11):1496–500.CrossRefPubMed Capitanio U, Cloutier V, Zini L, Isbarn H, Jeldres C, Shariat SF, et al. A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study. BJU Int. 2009;103(11):1496–500.CrossRefPubMed
12.
go back to reference Leibovich BC, Lohse CM, Crispen PL, Boorjian SA, Thompson RH, Blute ML, et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol. 2010;183(4):1309–15.CrossRefPubMed Leibovich BC, Lohse CM, Crispen PL, Boorjian SA, Thompson RH, Blute ML, et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol. 2010;183(4):1309–15.CrossRefPubMed
13.
go back to reference Keegan KA, Schupp CW, Chamie K, Hellenthal NJ, Evans CP, Koppie TM. Histopathology of surgically treated renal cell carcinoma: survival differences by subtype and stage. J Urol. 2012;188(2):391–7.CrossRefPubMedPubMedCentral Keegan KA, Schupp CW, Chamie K, Hellenthal NJ, Evans CP, Koppie TM. Histopathology of surgically treated renal cell carcinoma: survival differences by subtype and stage. J Urol. 2012;188(2):391–7.CrossRefPubMedPubMedCentral
14.
15.
go back to reference Hakimi AA, Reznik E, Lee CH, Creighton CJ, Brannon AR, Luna A, et al. An integrated metabolic atlas of clear cell renal cell carcinoma. Cancer Cell. 2016;29(1):104–16.CrossRefPubMedPubMedCentral Hakimi AA, Reznik E, Lee CH, Creighton CJ, Brannon AR, Luna A, et al. An integrated metabolic atlas of clear cell renal cell carcinoma. Cancer Cell. 2016;29(1):104–16.CrossRefPubMedPubMedCentral
16.
go back to reference Orduña-Castillo LB, Del-Río-Robles JE, García-Jiménez I, Zavala-Barrera C, Beltrán-Navarro YM, Hidalgo-Moyle JJ, et al. Calcium sensing receptor stimulates breast cancer cell migration via the Gβγ-AKT-mTORC2 signaling pathway. J Cell Commun Signal. 2022;16(2):239–52.CrossRefPubMed Orduña-Castillo LB, Del-Río-Robles JE, García-Jiménez I, Zavala-Barrera C, Beltrán-Navarro YM, Hidalgo-Moyle JJ, et al. Calcium sensing receptor stimulates breast cancer cell migration via the Gβγ-AKT-mTORC2 signaling pathway. J Cell Commun Signal. 2022;16(2):239–52.CrossRefPubMed
17.
go back to reference Agarwal NK, Kim CH, Kunkalla K, Vaghefi A, Sanchez S, Manuel S, et al. Smoothened (SMO) regulates insulin-like growth factor 1 receptor (IGF1R) levels and protein kinase B (AKT) localization and signaling. Lab Invest. 2022;102(4):401–10.CrossRefPubMed Agarwal NK, Kim CH, Kunkalla K, Vaghefi A, Sanchez S, Manuel S, et al. Smoothened (SMO) regulates insulin-like growth factor 1 receptor (IGF1R) levels and protein kinase B (AKT) localization and signaling. Lab Invest. 2022;102(4):401–10.CrossRefPubMed
18.
go back to reference Khan SU, Ahemad N, Chuah LH, Naidu R, Htar TT. Natural bioactive compounds as a new source of promising G protein-coupled estrogen receptor (GPER) modulators: comprehensive in silico approach. J Biomol Struct Dyn. 2022;40(4):1617–28.CrossRefPubMed Khan SU, Ahemad N, Chuah LH, Naidu R, Htar TT. Natural bioactive compounds as a new source of promising G protein-coupled estrogen receptor (GPER) modulators: comprehensive in silico approach. J Biomol Struct Dyn. 2022;40(4):1617–28.CrossRefPubMed
19.
go back to reference Li Z, Liu J, Inuzuka H, Wei W. Functional analysis of the emerging roles for the KISS1/KISS1R signaling pathway in cancer metastasis. J Genet Genomics. 2022;49(3):181–4.CrossRefPubMed Li Z, Liu J, Inuzuka H, Wei W. Functional analysis of the emerging roles for the KISS1/KISS1R signaling pathway in cancer metastasis. J Genet Genomics. 2022;49(3):181–4.CrossRefPubMed
20.
go back to reference Pagano E, Elias JE, Schneditz G, Saveljeva S, Holland LM, Borrelli F, et al. Activation of the GPR35 pathway drives angiogenesis in the tumour microenvironment. Gut. 2022;71(3):509–20.CrossRefPubMed Pagano E, Elias JE, Schneditz G, Saveljeva S, Holland LM, Borrelli F, et al. Activation of the GPR35 pathway drives angiogenesis in the tumour microenvironment. Gut. 2022;71(3):509–20.CrossRefPubMed
21.
go back to reference He J, Meng M, Wang HA. Novel prognostic biomarker LPAR6 in hepatocellular carcinoma via associating with immune infiltrates. J Clin Transl Hepatol. 2022;10(1):90–103.CrossRefPubMed He J, Meng M, Wang HA. Novel prognostic biomarker LPAR6 in hepatocellular carcinoma via associating with immune infiltrates. J Clin Transl Hepatol. 2022;10(1):90–103.CrossRefPubMed
22.
go back to reference Tsutsumi E, Stricklin J, Peterson EA, Schroeder JA, Kim S. Cxcl10 chemokine induces migration of ING4-deficient breast cancer cells via a novel cross talk mechanism between the Cxcr3 and Egfr receptors. Mol Cell Biol. 2022;42(2):e0038221.CrossRefPubMed Tsutsumi E, Stricklin J, Peterson EA, Schroeder JA, Kim S. Cxcl10 chemokine induces migration of ING4-deficient breast cancer cells via a novel cross talk mechanism between the Cxcr3 and Egfr receptors. Mol Cell Biol. 2022;42(2):e0038221.CrossRefPubMed
23.
go back to reference Thana M, Basappa NS, Ghosh S, Kollmannsberger CK, Heng DYC, Hansen AR, et al. Utilization and safety of ipilimumab plus nivolumab in a real-world cohort of metastatic renal cell carcinoma patients. Clin Genitourin Cancer. 2022;20(3):210–8.CrossRefPubMed Thana M, Basappa NS, Ghosh S, Kollmannsberger CK, Heng DYC, Hansen AR, et al. Utilization and safety of ipilimumab plus nivolumab in a real-world cohort of metastatic renal cell carcinoma patients. Clin Genitourin Cancer. 2022;20(3):210–8.CrossRefPubMed
24.
go back to reference Dagher J, Brunot A, Evrard B, Kammerer-Jacquet SF, Beaumont M, Cornevin L, et al. Multiple metastatic clones assessed by an integrative multiomics strategy in clear cell renal carcinoma: a case study. J Clin Pathol. 2022;75(6):426–30.CrossRefPubMed Dagher J, Brunot A, Evrard B, Kammerer-Jacquet SF, Beaumont M, Cornevin L, et al. Multiple metastatic clones assessed by an integrative multiomics strategy in clear cell renal carcinoma: a case study. J Clin Pathol. 2022;75(6):426–30.CrossRefPubMed
25.
go back to reference Chakiryan NH, Hajiran A, Kim Y, Aydin AM, Zemp L, Katende E, et al. Correlating immune cell infiltration patterns with recurrent somatic mutations in advanced clear cell renal cell carcinoma. Eur Urol Focus. 2022;8(3):784–93.CrossRefPubMed Chakiryan NH, Hajiran A, Kim Y, Aydin AM, Zemp L, Katende E, et al. Correlating immune cell infiltration patterns with recurrent somatic mutations in advanced clear cell renal cell carcinoma. Eur Urol Focus. 2022;8(3):784–93.CrossRefPubMed
26.
go back to reference Siva S, Bressel M, Wood ST, Shaw MG, Loi S, Sandhu SK, et al. Stereotactic radiotherapy and short-course pembrolizumab for oligometastatic renal cell carcinoma-the RAPPORT trial. Eur Urol. 2022;81(4):364–72.CrossRefPubMed Siva S, Bressel M, Wood ST, Shaw MG, Loi S, Sandhu SK, et al. Stereotactic radiotherapy and short-course pembrolizumab for oligometastatic renal cell carcinoma-the RAPPORT trial. Eur Urol. 2022;81(4):364–72.CrossRefPubMed
27.
go back to reference Tsuboi I, Ogawa K, Yokoyama S, Araki A, Kadota K, Wada K. Open partial nephrectomy of a left-to-right crossed fused renal ectopia with clear cell renal cell carcinoma: case report and review of the literature. Urol Case Rep. 2022;41: 101964.CrossRefPubMed Tsuboi I, Ogawa K, Yokoyama S, Araki A, Kadota K, Wada K. Open partial nephrectomy of a left-to-right crossed fused renal ectopia with clear cell renal cell carcinoma: case report and review of the literature. Urol Case Rep. 2022;41: 101964.CrossRefPubMed
28.
go back to reference Situ Y, Xu Q, Deng L, Zhu Y, Gao R, Lei L, et al. SysTME analysis of VEGFA in renal cell carcinoma: the expression, prognosis, gene regulation network and regulation targets. Int J Biol Markers. 2022;37(1):90–101.CrossRefPubMed Situ Y, Xu Q, Deng L, Zhu Y, Gao R, Lei L, et al. SysTME analysis of VEGFA in renal cell carcinoma: the expression, prognosis, gene regulation network and regulation targets. Int J Biol Markers. 2022;37(1):90–101.CrossRefPubMed
29.
go back to reference Kubiliūtė R, Žukauskaitė K, Žalimas A, Ulys A, Sabaliauskaitė R, Bakavičius A, et al. Clinical significance of novel DNA methylation biomarkers for renal clear cell carcinoma. J Cancer Res Clin Oncol. 2022;148(2):361–75.CrossRefPubMed Kubiliūtė R, Žukauskaitė K, Žalimas A, Ulys A, Sabaliauskaitė R, Bakavičius A, et al. Clinical significance of novel DNA methylation biomarkers for renal clear cell carcinoma. J Cancer Res Clin Oncol. 2022;148(2):361–75.CrossRefPubMed
30.
go back to reference Chalbatani GM, Momeni SA, Mohammadi Hadloo MH, Karimi Z, Hadizadeh M, Jalali SA, et al. Comprehensive analysis of ceRNA networks to determine genes related to prognosis, overall survival, and immune infiltration in clear cell renal carcinoma. Comput Biol Med. 2022;141: 105043.CrossRefPubMed Chalbatani GM, Momeni SA, Mohammadi Hadloo MH, Karimi Z, Hadizadeh M, Jalali SA, et al. Comprehensive analysis of ceRNA networks to determine genes related to prognosis, overall survival, and immune infiltration in clear cell renal carcinoma. Comput Biol Med. 2022;141: 105043.CrossRefPubMed
31.
go back to reference Kuczler MD, Zieren RC, Dong L, de Reijke TM, Pienta KJ, Amend SR. Advancements in the identification of EV derived mRNA biomarkers for liquid biopsy of clear cell renal cell carcinomas. Urology. 2022;160:87–93.CrossRefPubMed Kuczler MD, Zieren RC, Dong L, de Reijke TM, Pienta KJ, Amend SR. Advancements in the identification of EV derived mRNA biomarkers for liquid biopsy of clear cell renal cell carcinomas. Urology. 2022;160:87–93.CrossRefPubMed
32.
go back to reference Benamran D, Albiges L, Bex A, Giannarini G, Capitanio U, Rouprêt M. Treatment options for de novo metastatic clear-cell renal cell carcinoma: current recommendations and future insights. Eur Urol Oncol. 2022;5(1):125–33.CrossRefPubMed Benamran D, Albiges L, Bex A, Giannarini G, Capitanio U, Rouprêt M. Treatment options for de novo metastatic clear-cell renal cell carcinoma: current recommendations and future insights. Eur Urol Oncol. 2022;5(1):125–33.CrossRefPubMed
Metadata
Title
Exploring oncogenes for renal clear cell carcinoma based on G protein-coupled receptor-associated genes
Authors
Chengcun Zhu
Zhou Sun
Jie Wang
Xiangdi Meng
Zhaosen Ma
Rui Guo
Jiqiang Niu
Lisa Jia Tran
Jing Zhang
Tianxiao Jiang
Yunfei Liu
Fangdie Ye
Baoluo Ma
Publication date
01-12-2023
Publisher
Springer US
Published in
Discover Oncology / Issue 1/2023
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-023-00795-z

Other articles of this Issue 1/2023

Discover Oncology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine